Moderna, Pfizer Covid shots: the preferred choice of nations
April 17 2021 12:17 AM
RELATED STORIES
Moderna-Pfizer

Reuters/New York

Wealthy governments are looking to Covid-19 shots from Pfizer and Moderna to keep their vaccination programmes on track, as safety concerns and production problems sideline vaccines from AstraZeneca and Johnson & Johnson, public health experts and industry analysts say.
Countries in Europe and Asia, as well as South Africa, are limiting or halting use of AstraZeneca’s shot over safety concerns.
Rollout of J&J’s one-shot vaccine was paused in the US and Europe this week over a handful of cases of very rare but dangerous blood clots in the brain, much like AstraZeneca’s safety issue.
The US Food and Drug Administration said it was studying whether the technology behind both vaccines was connected to the clotting cases.
Both use a modified cold virus as a vector to deliver coronavirus proteins into cells and prompt an immune response.
Combined, the two vaccines are supposed to account for more than 25% of global supply in 2021, according to a Reuters tally of public statements and media reports.
The vaccines from Pfizer with German partner BioNTech SE and Moderna use a different method to protect against Covid-19 that relies on messenger RNA (mRNA) to program cells to generate immunity to the coronavirus.
Those two shots were already viewed as a preferred choice among wealthy countries, analysts said, based on clinical trial data showing they were more than 90% effective at preventing symptomatic Covid-19. About 120mn Americans have received a Pfizer or Moderna shot so far with no major safety issue identified.
Now, the US and European Union are pushing to stock up on even more of the mRNA vaccines.
Japan is also working to secure 100mn doses of Pfizer’s shot by the end of June.
“Right now, (mRNA-based shots) are the Lamborghinis or McLarens of Covid-19 vaccines,” said Dr Peter Hotez, a vaccine researcher at Baylor College of Medicine in Houston, referring to ultra high-end luxury automobiles. J&J and AstraZeneca did not immediately respond to requests for comment.
Both Moderna and Pfizer said they are working to increase output above their 2021 production targets of up to 1bn and 2.5bn shots, respectively.
Pfizer this week said it is targeting a 10% increase in US dose deliveries through May and 50mn more doses for Europe in the second quarter of 2021.
The EU is also negotiating for up to 1.8bn Pfizer doses for 2022 and 2023.
German biotech CureVac, which is testing its own mRNA vaccine, yesterday  said requests for its shot have increased over the past few days following the J&J pause.
It expects to file for European authorisation in late May or early June.
The higher cost, production limits and demanding requirements for shipping and storage could limit mRNA-based vaccines’ availability in lower income countries, experts said.
“The raw materials needed for mRNA manufacturing and production are not cheap right now,” said Hartaj Singh, a biotechnology analyst at Oppenheimer & Co.
“In the second half of this year, we’ll see the conversation change to, ‘okay, how can we help the developing world get their hands on mRNA vaccines,’” Singh said of countries like the US, which has pledged to do so.
Moderna chief executive Stephane Bancel reiterated this week that his company would be able to significantly increase production in 2022.
Reuters on Wednesday reported that Moderna was talking to a US company with capacity to produce 30mn doses of its shot each month.
But poorer countries will likely still have to rely on the vaccines from J&J, AstraZeneca and others from China and Russia that unlike the mRNA shots can be stored in a standard refrigerator, making them a better option for rural and hard to reach areas.
That could change, said Amesh Adalja, senior scholar at Johns Hopkins Center for Health Security. “Hopefully, there will be innovation around the storage of mRNA vaccines that allows them to be used more widely,” he said.



There are no comments.

LEAVE A COMMENT Your email address will not be published. Required fields are marked*
MORE NEWS

HAPPENING IN DOHAMore